Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Goodwill & Intangibles: 2024-2025

Historic Goodwill & Intangibles for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $18.8 million.

  • Day One Biopharmaceuticals' Goodwill & Intangibles rose 16.03% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year increase of 16.03%. This contributed to the annual value of $15.6 million for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Goodwill & Intangibles stood at $18.8 million for Q3 2025, which was down 4.05% from $19.6 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Goodwill & Intangibles peaked at $20.4 million during Q1 2025, and registered a low of $15.6 million during Q4 2024.
  • Its 2-year average for Goodwill & Intangibles is $17.9 million, with a median of $17.8 million in 2024.
  • Data for Day One Biopharmaceuticals' Goodwill & Intangibles shows a peak YoY climbed of 16.71% (in 2025) over the last 5 years.
  • Over the past 2 years, Day One Biopharmaceuticals' Goodwill & Intangibles (Quarterly) stood at $15.6 million in 2024, then increased by 16.03% to $18.8 million in 2025.
  • Its Goodwill & Intangibles stands at $18.8 million for Q3 2025, versus $19.6 million for Q2 2025 and $20.4 million for Q1 2025.